ALNYLAM PHARMACEUTICALS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ALNYLAM PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $33.76M, a 58.35% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $13.75M, a 73.03% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $80.42M, a 11.20% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $81.06M, a 42.22% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $229.70M, a 19.20% decline from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $284.28M, a 148.83% increase from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $114.25M, a 56.66% decline from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $263.61M, a 13.39% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $33.76M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $13.75M 10-Q · filed 2026-07-30 | |
| 2025-12-31 | $229.70M 10-K · filed 2026-02-12 | |
| 2025-09-30 | $80.42M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $81.06M 10-Q · filed 2026-07-30 | |
| 2025-03-31 | $50.98M 10-Q · filed 2026-07-30 | |
| 2024-12-31 | $284.28M 10-K · filed 2026-02-12 | |
| 2024-09-30 | $90.57M 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $140.29M 10-Q · filed 2025-10-30 | |
| 2024-03-31 | $24.77M 10-Q · filed 2025-10-30 | |
| 2023-12-31 | $114.25M 10-K · filed 2026-02-12 | |
| 2023-09-30 | $24.90M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $38.12M 10-Q · filed 2024-10-31 | |
| 2023-03-31 | $26.42M 10-Q · filed 2024-10-31 | |
| 2022-12-31 | $263.61M 10-K · filed 2025-02-13 | |
| 2022-09-30 | $153.28M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $13.89M 10-Q · filed 2023-11-02 | |
| 2022-03-31 | $28.06M 10-Q · filed 2023-11-02 | |
| 2021-12-31 | $232.49M 10-K · filed 2024-02-15 | |
| 2021-09-30 | $71.50M 10-Q · filed 2022-10-27 | |
| 2021-06-30 | $75.45M 10-Q · filed 2022-10-27 | |
| 2021-03-31 | $47.03M 10-Q · filed 2022-10-27 | |
| 2020-12-31 | $189.37M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $32.21M 10-Q · filed 2021-10-28 | |
| 2020-06-30 | $91.87M 10-Q · filed 2021-10-28 | |
| 2020-03-31 | $54.22M 10-Q · filed 2021-10-28 | |
| 2019-12-31 | $63.50M 10-K · filed 2022-02-10 | |
| 2019-09-30 | $9.30M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $6.18M 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $11.41M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $60.74M 10-K · filed 2021-02-11 | |
| 2018-09-30 | $13.50M 10-Q · filed 2019-10-31 | |
| 2018-06-30 | $2.56M 10-Q · filed 2019-10-31 | |
| 2018-03-31 | $41.89M 10-Q · filed 2019-10-31 | |
| 2017-12-31 | $80.55M 10-K · filed 2020-02-13 | |
| 2016-12-31 | $11.61M 10-K · filed 2019-02-14 | |
| 2015-12-31 | $29.43M 10-K · filed 2018-02-15 | |
| 2014-12-31 | $28.45M 10-K · filed 2017-02-15 | |
| 2013-12-31 | $27.99M 10-K · filed 2016-02-12 | |
| 2012-12-31 | $6.40M 10-K · filed 2015-02-13 | |
| 2011-12-31 | $103.00K 10-K · filed 2014-02-20 | |
| 2010-12-31 | $1.73M 10-K · filed 2013-02-19 | |
| 2009-12-31 | $1.46M 10-K · filed 2012-02-13 | |
| 2008-12-31 | $3.79M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |